The goal of this clinical research study is to learn if the combination of blinatumomab and ponatinib can help to control Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL); BCR-ABL-positive ALL; or ALL that has come back (relapsed) or has not responded to treatment (refractory). Ph+ and BCR-ABL positive are types of genetic mutations (changes). The safety of this drug combination will also be studied.